Dandelion

Dandelion (Taraxacum mongolicum, closely related to T. officinale) significantly reduces oral bioavailability of ciprofloxacin in rats by 35% through chelation of the antibiotic by dandelion minerals (calcium, magnesium, iron, zinc) in the gastrointestinal tract, forming insoluble non-absorbable complexes. Dandelion fibre may additionally reduce gut transit time, further limiting antibiotic absorption. Clinical relevance for T. officinale is probable.

Advise patients to take quinolone antibiotics at least 2 hours before or 4-6 hours after any dandelion preparation including teas, tinctures, and capsules. Do not rely on dandelion supplements during critical antibiotic courses for serious infections such as UTIs or respiratory infections.

Dandelion creates a dual potentially opposing interaction: dandelion greens contain substantial vitamin K (778 mcg/100g fresh weight) which may reduce warfarin anticoagulant efficacy via substrate competition. Simultaneously, dandelion root and leaf demonstrate mild platelet aggregation inhibitory activity (Neef H et al. 1996). Additionally, in vitro data suggests possible CYP1A2 inhibition by dandelion flavonoids, which could increase warfarin plasma levels. Net INR effect is unpredictable.

Advise patients on warfarin to maintain consistent dandelion consumption to avoid INR fluctuations. Avoid starting high-dose dandelion supplementation without INR monitoring. Check INR within 1-2 weeks of any change in dandelion intake. Alert anticoagulation clinics to dandelion use.

Dandelion leaf ethanolic extract demonstrated statistically significant increases in urinary frequency and excretion ratio in a clinical pilot study in healthy volunteers (Clare et al. 2009). Co-administration with loop or thiazide diuretics produces additive diuretic effect and risk of electrolyte imbalance including hyponatraemia and hypokalaemia. Dandelion potassium content (~397 mg/100g) with potassium-sparing diuretics may cause hyperkalaemia.

Monitor electrolytes (especially sodium and potassium) in patients combining dandelion with prescription diuretics. Advise patients about signs of electrolyte imbalance such as muscle cramps, weakness, and irregular heartbeat. Caution patients taking spironolactone or amiloride about the risk of hyperkalaemia from dandelion potassium content.

Dandelion root and leaf extracts demonstrate hypoglycaemic activity in animal models through stimulation of insulin secretion from pancreatic islets and enhancement of peripheral glucose uptake. A documented human case report describes hypoglycaemia secondary to dandelion ingestion in a non-diabetic individual. Additive blood glucose lowering with antidiabetic medications increases hypoglycaemia risk, especially with sulfonylureas and insulin.

Advise diabetic patients using dandelion supplements to monitor blood glucose more frequently. Greatest risk is with insulin and sulfonylureas. Educate patients on signs and treatment of hypoglycaemia. Alert prescribers so antidiabetic doses can be reviewed if glucose targets are being undershot.

Dandelion exerts clinically demonstrable diuretic effects, increasing urinary sodium and fluid excretion. Increased urinary output and sodium loss triggers compensatory tubular reabsorption of sodium (and co-transported lithium) in the kidney, elevating plasma lithium concentrations to potentially toxic levels. Lithium has a very narrow therapeutic index (0.6-1.2 mEq/L), and small increases in plasma concentration can cause serious toxicity.

Avoid combining dandelion supplements with lithium therapy. If patients insist on using dandelion, monitor plasma lithium levels more frequently. Educate patients on signs of lithium toxicity including tremor, ataxia, confusion, polyuria, and nausea. Ensure adequate fluid and sodium intake to minimise lithium fluctuation.

Taraxacum officinale inhibits CYP1A2 enzyme activity in vitro and in animal pharmacokinetic models. This inhibition may reduce hepatic metabolism of CYP1A2-dependent drugs, resulting in elevated plasma concentrations. For narrow-therapeutic-index CYP1A2 substrates like theophylline (risk of seizures/arrhythmia) and clozapine (risk of agranulocytosis, sedation), even modest plasma level increases can produce clinically significant toxicity.

Monitor patients on theophylline, clozapine, or other narrow-TI CYP1A2 substrates for signs of drug toxicity if dandelion preparations are added. Consider drug level monitoring (serum theophylline, clozapine levels). MedicineNet lists dandelion may increase levels of propranolol, amitriptyline, haloperidol, and ondansetron via reduced liver breakdown.

Taraxacum officinale leaf extracts demonstrated significant diuretic activity in a human pilot study, with clinically meaningful increases in urinary frequency and excretion ratio (Clare et al. 2009). This pharmacodynamic diuretic effect, when combined with antihypertensive drugs that also lower blood pressure via other mechanisms (ACE inhibition, beta-blockade, calcium channel antagonism), may produce additive or excessive blood pressure-lowering, risking symptomatic hypotension.

Monitor blood pressure in patients using dandelion preparations alongside antihypertensive medications, particularly in the elderly or patients already at or below target BP. Advise adequate fluid intake. Dose adjustment of antihypertensives may be required if dandelion causes additional BP reduction.

Taraxacum officinale root components have demonstrated antiplatelet activity via inhibition of collagen-induced platelet aggregation in vitro (Jedrejek D et al. 2019). NSAIDs independently inhibit platelet aggregation through COX-1 blockade. Combined use creates additive antiplatelet activity, modestly increasing bleeding risk. Both agents also share anti-inflammatory COX pathway modulation.

Patients taking regular NSAID therapy should exercise caution with high-dose dandelion supplementation due to additive antiplatelet effects. Monitor for signs of unusual bruising or prolonged bleeding. Patients at increased GI bleeding risk (e.g., PUD) should be particularly cautious.

Dandelion leaves are a rich source of dietary potassium. Concurrent use with potassium-sparing diuretics (spironolactone, amiloride, triamterene), ACE inhibitors, or ARBs — all of which independently elevate serum potassium — creates a pharmacodynamic interaction that may cause clinically significant hyperkalemia. Hyperkalemia can produce life-threatening cardiac arrhythmias, particularly in patients with CKD or on digoxin.

Avoid high-dose dandelion supplementation in patients on potassium-sparing drugs. Monitor serum potassium and renal function in patients who insist on concurrent use. Counsel patients that dandelion leaves in food amounts are unlikely to be problematic, but supplemental doses may significantly raise serum potassium.